ArticleBMC neurology2022

The REACT study: design of a randomized phase 3 trial to assess the efficacy and safety of clazosentan for preventing deterioration due to delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage.

Nicolas Bruder et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.